Detalles de la búsqueda
1.
Short-, mid- and long-term efficacy of dupilumab in moderate to severe atopic dermatitis: a real life multicenter Italian study on 2576 patients.
Clin Exp Dermatol
; 2024 Jun 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38860563
2.
Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate-to-severe atopic dermatitis: A nationwide retrospective cohort study.
J Eur Acad Dermatol Venereol
; 2024 Jan 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38284131
3.
"Your Skin Tells You" Campaign for Keratinocyte Cancers: When Individuals' Selection Makes the Difference.
Dermatology
; 239(3): 387-392, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36754039
4.
Bath-PUVA still represents a valuable treatment option for the subsets of psoriatic patients who are not eligible to or rejecting systemic treatments and are not responsive to NB-UVB phototherapy.
Photodermatol Photoimmunol Photomed
; 39(4): 351-356, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-36398948
5.
A Short Cycle of Narrow-Band UVB Phototherapy in the Early Phase of Dupilumab Therapy Can Provide a Quicker Improvement of Severe Atopic Dermatitis.
Dermatology
; 237(3): 407-415, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33401279
6.
A Critical Reappraisal of Off-Label Use of Photodynamic Therapy for the Treatment of Non-Neoplastic Skin Conditions.
Dermatology
; 237(2): 262-276, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-32554971
7.
Clinical outcomes and management of JAK inhibitor-associated acne in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: A multicenter retrospective study.
J Am Acad Dermatol
; 90(5): 1031-1034, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38199282
8.
Survival, efficacy and safety of tralokinumab after 32 and 52 weeks of treatment for moderate-to-severe atopic dermatitis in adults: A multicentre real-world study.
J Eur Acad Dermatol Venereol
; 38(1): e11-e13, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37483150
9.
Beneficial effects of upadacitinib on alopecia areata associated with atopic dermatitis: A multicenter retrospective study.
J Am Acad Dermatol
; 89(6): 1251-1253, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37169293
10.
Long-term drug survival of dupilumab and associated predictors in moderate-to-severe atopic dermatitis: A real-world prospective cohort study.
J Eur Acad Dermatol Venereol
; 37(6): e757-e759, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36662631
11.
A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis.
J Eur Acad Dermatol Venereol
; 37(3): e384-e388, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36225088
12.
Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID-19 pandemic: A single-center real-life experience.
Dermatol Ther
; 33(4): e13765, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32500660
13.
UVA1 phototherapy as a treatment option for plaque psoriasis in HIV-positive patients.
Photodermatol Photoimmunol Photomed
; 36(6): 478-480, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32473061
14.
A Multidisciplinary Approach Is Beneficial in Atopic Dermatitis.
Dermatol Ther (Heidelb)
; 14(6): 1443-1455, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38811470
15.
Drug Survival of Upadacitinib and Predicting Factors of Discontinuation in Adult Patients Affected by Moderate-to-Severe Atopic Dermatitis: An Italian Multicenter Analysis.
J Clin Med
; 13(2)2024 Jan 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38256686
16.
AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History.
Am J Clin Dermatol
; 25(1): 149-160, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37725229
17.
Italian S3-Guideline on the treatment of Atopic Eczema - Part 1: Systemic therapy, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Environmental Dermatology (SIDAPA).
Ital J Dermatol Venerol
; 159(3): 223-250, 2024 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38727633
18.
Italian S3-Guideline on the treatment of Atopic Eczema - First Update, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Occupational Dermatology (SIDAPA).
Ital J Dermatol Venerol
; 159(3): 279-284, 2024 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38727635
19.
Italian S3-Guideline on the treatment of Atopic Eczema - Part 2: non-systemic treatments and treatment recommendations for special AE patient populations, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Occupational Dermatology (SIDAPA).
Ital J Dermatol Venerol
; 159(3): 251-278, 2024 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38727634
20.
The realistic positioning of UVA1 phototherapy after 25 years of clinical experience and the availability of new biologics and small molecules: a retrospective clinical study.
Front Med (Lausanne)
; 10: 1295145, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38076241